Lp(a): the hidden genetic heart-disease risk most people never test for

Most adults can rattle off their cholesterol number without much effort — LDL, HDL, maybe a total score from their last check-up. Far fewer have ever heard of Lp(a), a lesser-known, cholesterol-related particle that a new study says deserves far more attention. Researchers tracking more than 20,000 people found that very high levels of Lp(a) were linked to a significantly greater risk of major cardiovascular events, particularly stroke and cardiovascular death.

The particle, short for lipoprotein(a), circulates in the blood alongside more familiar fats like LDL cholesterol. What makes it different — and, researchers say, more dangerous for some people — is an extra protein called apolipoprotein(a) attached to its surface. That protein appears to make Lp(a) especially good at contributing to the fatty plaque buildup inside artery walls, while also interfering with the body's ability to break down blood clots.

Unlike LDL cholesterol, which shifts with diet, exercise, weight and medication, Lp(a) levels are determined almost entirely by genetics. A single gene inherited from your parents sets your Lp(a) level early in life, and it typically stays roughly the same from childhood onward. That means a person can eat well, exercise regularly and keep every other cardiovascular risk factor in check, and still carry a hidden, inherited risk that never shows up on the scale or the treadmill.

That genetic fixedness is also why so few people ever learn their number. Standard cholesterol panels, the blood tests ordered at a routine physical, typically measure total cholesterol, LDL, HDL and triglycerides — but not Lp(a). Testing for it requires a specific request, and many primary care doctors don't order it unless a patient has a strong family history of early heart disease or stroke, or unexplained cardiovascular events despite otherwise normal cholesterol.

According to the new research, elevated Lp(a) is far from rare. The study's authors estimate that roughly one in five people carry very high levels of the particle, a proportion that puts it in the same territory as more widely tested risk factors like high blood pressure. Because the association with stroke risk was particularly strong, researchers say the finding should prompt more clinicians to consider it in patients whose stroke risk otherwise seems unexplained.

The mechanism behind the stroke link isn't fully settled, but researchers point to Lp(a)'s dual role: it behaves like LDL in promoting artery-clogging plaque, while its apolipoprotein(a) component structurally resembles plasminogen, a protein the body uses to dissolve clots. By interfering with that clot-dissolving process, high Lp(a) may make it easier for clots to form and harder for the body to clear them once they do — a combination that raises the odds of a blockage reaching the brain.

Because levels are set for life, doctors who do order the test generally consider a single measurement sufficient — there's little value in repeat testing the way there is for LDL, which can change with treatment. Health authorities in several countries have begun recommending that every adult get their Lp(a) checked at least once, a low-cost, low-effort step that could flag a risk that would otherwise stay invisible for decades.

Knowing you carry high Lp(a) doesn't currently come with a dedicated treatment. No drug is yet widely approved specifically to lower Lp(a) levels, so cardiologists instead focus on managing everything else that can be controlled: driving down LDL cholesterol more aggressively, treating blood pressure, quitting smoking and, in higher-risk patients, prescribing anti-clotting medication. The logic is that reducing the other contributors to plaque and clotting can offset some of the danger posed by an elevated Lp(a) reading.

That may be about to change. Several pharmaceutical companies have Lp(a)-lowering drugs in late-stage clinical trials, using approaches ranging from small-molecule pills to gene-silencing injections that block the liver from producing as much apolipoprotein(a). Early results have shown some of these treatments can cut Lp(a) levels dramatically, though it's still being established whether lowering the particle directly translates into fewer heart attacks and strokes — the trials designed to answer that question are ongoing.

For now, the practical takeaway from the research is simple: a one-time blood test most people have never requested could reveal a risk factor that no amount of healthy living will change on its own — but that, once known, can still be managed. Cardiologists increasingly argue that Lp(a) belongs alongside blood pressure and standard cholesterol as a routine part of understanding your cardiovascular risk, rather than a niche test reserved for those who already have unexplained heart problems.